Last updated on April 2019

To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine

Brief description of study

Safety and tolerability of treatment with atogepant for the prevention of episodic migraine over the course of one year

Clinical Study Identifier: NCT03700320

Contact Investigators or Research Sites near you

Start Over

Clinical Neuroscience Solutions

Orlando, FL United States

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.